Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines

Cancer Research

Volumn 59, Issue 24, 1999, Pages 6178-6184

  Soriano, Ariel F ^a   Helfrich, Barbara ^a   Chan, Daniel C ^a   Heasley, Lynn E ^a   Bunn Jr , Paul A ^a   Chou, Ting Chao ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONATE 12 LIPOXYGENASE; CISPLATIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; ISOTRETINOIN; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PACLITAXEL; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL SURVIVAL; CHEMOPREVENTION; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; HUMANS; LIPOXYGENASE INHIBITORS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033572578     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. Cancer statistics. CA Cancer J. Clin., 48: 6-9, 1998.
2. Schottenfeld, D. Epidemiology of lung cancer. In: H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer, Principles and Practice, pp. 305-321. Philadelphia: Lippincott-Raven, 1996.
3. Strauss, G., DeCamp, M., Dibiccaro, E., Richards, W., Harpole, D., Heasley, E., and Sugarbaker, D. Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers. Proc. Am. Soc. Clin. Oncol., 14: 362, 1995.
4. Teicher, B., Korbut, T., Menon, K., Holden, S., and Ara, G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother. Pharmacol., 33: 515-522, 1996.
5. Chan, D. C., Geraci, M., and Bunn, P. A., Jr. Anti-growth factor therapy for lung cancer. Drug Resistance Updates. 1: 377-388, 1998.
6. Heasley, L., Thaler, S., Nicks, M., Price, B., Skorecki, K., and Nemenoff, R. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem., 6: 272-273, 1997.
7. Moody, T., Leyton, J., Martinez, A., Hong, S., Malkinson, A., and Mulshine, J. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp. Lung Res., 24: 617-628, 1998.
8. Rioux, N., and Castonguay, A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (Lond.), 19: 1393-1400, 1998.
9. Hida, T., Yatabe, Y., Achiwa, H., Muramutsa, H., Kozake, K., Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., and Takahashi, T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.
10. Wolff, H., Saukkonen, K., Anttila, S., Karjalainen, A., Vainio, H., and Ristimaki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997-5001, 1998.
11. Castonguay, A., and Rioux, N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis (Lond.), 18: 491-496, 1997.
12. Hida, T., Leyton, J., Makheja, A., Ben-Av, P., Hela, T., Martinez, A., Mulshine, J., Malkani, S., Chung, P., and Moody, T. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res., 18: 775-782, 1998.
13. Pepin, P., Bouchard, L., Nicole, P., and Castonguay, A. Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis (Lond.), 13: 341-348, 1992.
14. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res., 57: 2452-2459, 1997.
15. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Birt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
16. Thompson, H., Jiang, C., Lu, J., Mehta, R., Piazza, G., Paranka, N., Pamukcu, R., and Ahnen, D. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57: 267-271, 1997.
17. Malkinson, A., Koski, K., Dwyer-Nield, L., Rice, P., Rioux, N., Castonguay, A., Ahnen, D., Thompson, H., Pamukcu, R., and Piazza, G. Inhibition of 4-(methlynitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis (Lond.), 19: 1353-1356, 1998.
18. Thompson, W. J., Pamulku, R., Liu, L., Li, H., Ahnen, D., Speri, G., and Piazza, G. A. Exisulind (Prevatac) induced apoptosis in cultured colonie tumor cells involves inhibition of cyclic GMP phosphodiesterase. Proc. Am. Assoc. Cancer Res., 40: 4, 1999.
19. Duffy, C. P., Elliott, C. J., O'Connor, R. A., Heenan, M. M., Coyle, S., Cleary, I. M., Kavanagh, K., Verhaegen, S., O'Loughlin, C. M., Nicamhlaoibh, R., and Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs. Eur. J. Cancer, 34: 1250-1259, 1998.
20. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Walsh, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., and Testa, J. R. p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51: 4090-4096, 1991.
21. D'Amico, D., Carbone, D., and Mitsudomi, T. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene, 7: 339-346, 1992.
22. Carmichael, J., Mitchell, J. B., DeGraff, W. G., Gamson, J., Gadzar, A. F., Johnson, B. E., Glatstein, E., and Minna, J. D. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br. J. Cancer, 57: 540-547, 1988.
23. Chou, T. C., and Talalay, P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci., 4: 450-454, 1983.
24. Krishan, A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol., 66: 188-193, 1975.
25. Soriano, A., and Bunn, P. A., Jr. New drug combinations in NSCLC. In: G-Hortobagyi, and D. Khayat (eds.), Progress in Anti-Cancer Chemotherapy, pp. 131-171. Paris: Springer-Verlag, 1999.
26. Huang, M., Stolina, M., Sharma, S., Mao, J. T., Zhu, L., Miller, P. W., Wollman, J., Hershman, H., and Dubinett, S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res., 58: 1208-1216, 1998.
27. Subbegowda, R., and Frommel, T. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res., 58: 2772-2776, 1998.
28. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
29. Piazza, G. A., Lloyd, M., David, M., Lim, J., Sperl, G., Li, H., Thompson, W., Pamukcu, R., and Weinstein, I. Selective apoptosis of human prostate tumor cells by exisulind and an analog via a cyclooxygenase-independent pathway. Proc. Am. Assoc. Cancer Res., 40: 4, 1999.
30. Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Firket, P., Rosmentz, N., Clerici, M., Soresi, E., and Valente, M. Adjuvant treatment of stage 1 lung cancer with high dose vitamin A. J. Clin. Oncol., 11: 1216-1222, 1993.
31. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., and Peters, R. J. Prevention of second primary tumors with isoretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.